200 related articles for article (PubMed ID: 30240072)
1. Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study.
Yusuf A; Chia V; Xue F; Mikol DD; Bollinger L; Cangialose C
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1309-1315. PubMed ID: 30240072
[TBL] [Abstract][Full Text] [Related]
2. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry.
Ephross SA; Sinclair SM
Headache; 2014; 54(7):1158-72. PubMed ID: 24805878
[TBL] [Abstract][Full Text] [Related]
3. The safety of sumatriptan and naratriptan in pregnancy: what have we learned?
Cunnington M; Ephross S; Churchill P
Headache; 2009; 49(10):1414-22. PubMed ID: 19804390
[TBL] [Abstract][Full Text] [Related]
4. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
[TBL] [Abstract][Full Text] [Related]
5. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study.
Nezvalová-Henriksen K; Spigset O; Nordeng H
Headache; 2010 Apr; 50(4):563-75. PubMed ID: 20132339
[TBL] [Abstract][Full Text] [Related]
6. Triptan safety during pregnancy: a Norwegian population registry study.
Nezvalová-Henriksen K; Spigset O; Nordeng H
Eur J Epidemiol; 2013 Sep; 28(9):759-69. PubMed ID: 23884894
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study.
Spielmann K; Kayser A; Beck E; Meister R; Schaefer C
Cephalalgia; 2018 May; 38(6):1081-1092. PubMed ID: 28758416
[TBL] [Abstract][Full Text] [Related]
8. Use of 5-HT1 agonists in pregnancy.
Evans EW; Lorber KC
Ann Pharmacother; 2008 Apr; 42(4):543-9. PubMed ID: 18349309
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis.
Marchenko A; Etwel F; Olutunfese O; Nickel C; Koren G; Nulman I
Headache; 2015 Apr; 55(4):490-501. PubMed ID: 25644494
[TBL] [Abstract][Full Text] [Related]
10. Triptans in pregnancy.
Soldin OP; Dahlin J; O'Mara DM
Ther Drug Monit; 2008 Feb; 30(1):5-9. PubMed ID: 18223456
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
Blumenfeld A; Gennings C; Cady R
Headache; 2012 Apr; 52(4):636-47. PubMed ID: 22221151
[TBL] [Abstract][Full Text] [Related]
12. Safety of triptans for migraine headaches during pregnancy and breastfeeding.
Duong S; Bozzo P; Nordeng H; Einarson A
Can Fam Physician; 2010 Jun; 56(6):537-9. PubMed ID: 20547518
[TBL] [Abstract][Full Text] [Related]
13. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
14. Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance.
MacDonald SC; Cohen JM; Panchaud A; McElrath TF; Huybrechts KF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1211-1221. PubMed ID: 31328328
[TBL] [Abstract][Full Text] [Related]
15. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment.
Reiff-Eldridge R; Heffner CR; Ephross SA; Tennis PS; White AD; Andrews EB
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):159-63. PubMed ID: 10649172
[TBL] [Abstract][Full Text] [Related]
16. Preliminary results on pregnancy outcomes in women using lamotrigine.
Tennis P; Eldridge RR;
Epilepsia; 2002 Oct; 43(10):1161-7. PubMed ID: 12366730
[TBL] [Abstract][Full Text] [Related]
17. Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes.
Bérard A; Strom S; Zhao JP; Kori S; Albrecht D
Sci Rep; 2021 Sep; 11(1):19302. PubMed ID: 34588467
[TBL] [Abstract][Full Text] [Related]
18. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan.
Källén B; Lygner PE
Headache; 2001 Apr; 41(4):351-6. PubMed ID: 11318881
[TBL] [Abstract][Full Text] [Related]
19. Prenatal triptan exposure and neurodevelopmental outcomes in 5-year-old children: Follow-up from the Norwegian Mother and Child Cohort Study.
Harris GE; Wood M; Ystrom E; Nordeng H
Paediatr Perinat Epidemiol; 2018 May; 32(3):247-255. PubMed ID: 29569251
[TBL] [Abstract][Full Text] [Related]
20. Prenatal Triptan Exposure and Internalising and Externalising Behaviour Problems in 3-Year-Old Children: Results from the Norwegian Mother and Child Cohort Study.
Wood ME; Lapane K; Frazier JA; Ystrom E; Mick EO; Nordeng H
Paediatr Perinat Epidemiol; 2016 Mar; 30(2):190-200. PubMed ID: 26525300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
